Pharmaceuticals, Biotechnology and Life Sciences
Allergan has announced a collaboration with SonarMD on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes.
Canadian biopharmaceutical company Aeterna Zentaris, Inc., has signed an additional licensing agreement with Specialised Therapeutics Asia (“STA”) for its anti-cancer compound, Zoptrex.
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
THERADIAG a company specializing in in vitro diagnostics and theranostics, has reported its consolidated revenues for the 3rd quarter of 2016.
STENTYS a medical technology company today announced its revenue for the third quarter and first 9 months to September 30, 2016.
Allergan announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA).
SpineGuard announced today that its third quarter revenue grew to €1.7 million, a 2% increase compared with 3Q 2015.
Adocia a clinical stage biopharmaceutical company announced today third quarter revenue and net cash position ending September 30,2016.
Mauna Kea Technologies inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, announced today the launch of a ground-breaking new clinical study led by researchers at the University of Utah School of Medicine and Harvard Medical School called: “Evaluation of Fiberoptic Confocal Microscopy for Pediatric Cardiac Surgery.”
Bayer has announced that the acquisition facilities of USD 56.9 billion that Bayer had agreed with five underwriter banks (BofA Merrill Lynch, Credit Suisse, Goldman Sachs, HSBC and JP Morgan) prior to announcement of the Monsanto acquisition has now been successfully syndicated within the group of Bayer’s core relationship banks.